Clinical Trials
171 trialsLutécio
Instituto do Cancer do Estado de São Paulo
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
THUNDER
Cancer Research Antwerp
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
CONVERT-HB1
Fudan University
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Northwestern University
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Emory University
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Qilu Hospital of Shandong University
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
PKUFH-GS5
Peking University First Hospital
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead4Care
Uppsala University
ARASAFE
Jena University Hospital
GUNS
University of British Columbia
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
PEACE1
UNICANCER
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
University of California, San Diego
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer
Herlev Hospital
ECHOS
Santa Chiara Hospital
DOP
The Netherlands Cancer Institute
CHEIRON
Santa Chiara Hospital
OLIGOMET
Medical University of Vienna
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
University of Wisconsin, Madison
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Duke University
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Zhongnan Hospital
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
NYU Langone Health
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
University of Nebraska
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER